-
Novo Nordisk is significantly enhancing its footprint in the U.S. manufacturing industry with plans for facility expansion.
-
The administration has decided to hold off on imposing tariffs until negotiations conclude.
-
The pharmaceutical company is currently awaiting authorization to distribute an oral weight loss medication.
By 11:30 a.m. on Wednesday, shares in Novo Nordisk (NYSE: NVO) rose by 6%. This increase follows Pfizer‘s recent agreement with the Trump administration, raising optimism that other pharmaceutical firms, including Novo Nordisk, might achieve similar arrangements.
The administration’s goal is to restore pharmaceutical manufacturing to the United States. President Donald Trump threatened to impose 100% tariffs on “any branded or patented Pharmaceutical Product,” as stated in a post on Truth Social. This action is particularly directed towards pharmaceutical manufacturers, whether domestic or international, that produce medications abroad and import them for sale in the U.S.
However, Pfizer has confirmed that its agreement includes a three-year grace period before tariffs go into effect, contingent upon the company increasing its U.S. manufacturing investments. The firm has voluntarily “committed to implementing measures that ensure Americans receive drug prices comparable to those in other advanced nations.”
Even though Novo Nordisk is a European enterprise, it possesses a considerable manufacturing presence in North Carolina and is making a substantial $4.1 billion investment in expanding its operations there. Additionally, Commerce Secretary Howard Lutnick has indicated that tariffs will not be applied until discussions with pharmaceutical companies have been finalized.
This news raises hopes that Novo Nordisk might secure a similar agreement just as it waits for the green light to market an oral weight loss drug — one compelling reason to consider purchasing the stock in 2025.
Before investing in Novo Nordisk, please take note:
The Motley Fool Stock Advisor analysis team recently highlighted what they believe are the 10 top stocks to buy right now… and Novo Nordisk wasn’t included among them. The 10 stocks that were selected hold the potential for substantial returns in the future.
To put this into perspective, when Netflix was recommended on December 17, 2004, a $1,000 investment would have grown to $646,567!* Likewise, a $1,000 investment in Nvidia when it was listed on April 15, 2005, would have turned into $1,143,710!*
